Monday, June 6, 2016

Alexion Drug Misses Goal in Neuromuscular Disease Study

A late-stage study of Alexion Pharmaceuticals’ Soliris drug to treat a rare neuromuscular disease didn’t meet its primary goal.

from WSJ.com: US Business http://ift.tt/1td9YBh
via IFTTT
Posted by at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)